OPEN ACCESS Freely available online

ISSN: 2167-7956
Journal of
Biomolecular Research
& Therapeutics

Perspective

Nanotechnology and its Advances in the Treatment of Diabetic Patients

Niki Simos*

Department of Biomolecules, University of Ioannina, Ioannina, Greece

DESCRIPTION

A nanoparticle in hypertension development has contributed to the creation of innovative sugar measuring and hormone administration mechanisms which have the potential to significantly enhance patients' life quality. It focuses on recent advances in insulin at the intersection of nanomaterial's. It focuses on glucose detection with nanomaterials such as Nano crystals and carbon nanomaterial. The incorporation of nanomaterial often improves hypoglycemia sensor sensitivity and temporal response and can result in sensors that allow for continuously in glucose meters. In addition nanotechnology approaches to "closed-loop" insulin administrations that lead to insulin resistance continuously in response to varying blood glucose levels. Diabetes is a metabolic condition marked by continuously increased Blood Glucose Levels (BGLs) and the failure to maintain BGL people with type 1 diabetes are unable to make glucose due to inflammatory loss of the pancreatic auxin cells known as beta cells. Metabolic syndrome or a lack of cellular responsiveness to glucose in the circulation characterizes type 2 diabetes. In both circumstances the loss of homeostasis-regulating processes can result in persistently elevated or low blood glucose levels known as hyperglycemia and hypoglycemia, respectively.

Persistent hyperglycemia can cause a number of symptoms involving cardiac and neurodegenerative complications whereas hypoglycemia can cause fatigue, exhaustion and death. Diabetic Nephropathy (DN) is a term used to describe a range of physiological illnesses hyperglycaemia. Oral subcutaneously delivered diabetes medications including such glucagon, glipalamide and hydrochloride can immediately control cholesterol levels however long-term use of these medications is connected with unpleasant. Diabetics are also at a high risk of getting related to oxidant excess production and reactive hypoglycemia cerebrovascular disease system damage. The potential benefits of applying nanomaterial to healthcare include having access to tiny and significant sections of cells and detection of small amounts of analyses. Furthermore the advent of quantum effects results in the formation of fascinating and valuable physical attributes such as microscopic carbon which is more powerful than highly bendable, luminescent and has corrosion resistant depicts typical nanomaterials for medical therapy. Improved hypoglycemia technology for example has an immediate and material influence on diabetic healthcare as enhanced sensing leads to more precise insulin administration and kidney disease management. Improvement to therapy is lowered in conjunction with the appearance of adverse reactions. Nanoparticles have found fruitful foundation in the production of innovative delivery mechanisms that have the potential to improve the effectiveness of anti-diabetic treatments in recent years. All attempts have focused on three critical steps protecting the medicine by enclosing it in a nano-carrier technology and efficiently releasing the drug in a controlled and progressive way. Nanoparticles has enabled significant advancements in both biosensor and self-regulated insulin delivery systems. Nanotechnology-enabled impedimetric devices now enable quick, reliable and very sensitivity glucose readings in bloodstream as well as other therapeutically relevant fluids such as tears and urine. Furthermore new developments in fluorescence glucose detection have the potential to provide constant in glucose monitoring. The development of sensors that do not require traditional clinical standard that avoid the discomfort, tissue injury and patient disobedience are highly desirable.

Correspondence to: Niki Simos, Department of Biomolecules, University of Ioannina, loannina, Greece, E-mail: simos@gmail.com

Received: 03-Feb-2023, Manuscript No. BOM-23-20720; **Editor assigned:** 06-Feb-2023, Pre QC No. BOM-23-20720(PQ); **Reviewed:** 21-Feb-2023, QC No. BOM-23-20720; **Revised:** 28-Feb-2023, Manuscript No. BOM-23-20720 (R); **Published:** 07-Mar-2023, DOI: 10.35248/2167-7956.23.12.268.

Citation: Simos N (2023) Nanotechnology and its Advances in the Treatment of Diabetic Patients. J Biol Res Ther. 12:268.